Buscar
Fortress Biotech Inc
FBIOAñadir a la lista de seguimiento
2.410USD
+0.110+4.78%
Cierre 05/15, 16:00（ET）Cotizaciones retrasadas 15 min
80.06MCap. mercado
0.63P/E TTM
Más Datos de Fortress Biotech Inc Compañía
Fortress Biotech, Inc. is a biopharmaceutical company focused on acquiring and advancing assets. The Company has eight marketed prescription pharmaceutical products and over 20 programs in development, with its majority-owned and majority-controlled partners and subsidiaries and partners and subsidiaries it founded and in which it holds significant minority ownership positions. Its portfolio is being commercialized and developed for various therapeutic areas, including oncology, dermatology, and rare diseases. Its dermatology products include Emrosi, Qbrexza, Amzeeq, Zilxi, Exelderm, Targadox, and Luxamend. Its late-stage product candidates include CUTX-101 (copper histidinate injection for Menkes disease), Triplex (cytomegalovirus (CMV) vaccine), and CAEL-101 (monoclonal antibody for AL amyloidosis). Its early and mid-stage product candidates include Dotinurad (urate transporter (URAT1) inhibitor for gout), MB-101 (IL13Rα2 CAR T Cell Program for Glioblastoma), and others.
Información de Fortress Biotech Inc
Símbolo de cotizaciónFBIO
Nombre de la empresaFortress Biotech Inc
Fecha de salida a bolsaNov 17, 2011
Director ejecutivoRosenwald (Lindsay A)
Número de empleados101
Tipo de seguridadOrdinary Share
Fin del año fiscalNov 17
Dirección1111 Kane Concourse
CiudadBAY HARBOR ISLANDS
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal33154
Teléfono17816524500
Sitio Webhttps://www.fortressbiotech.com/
Símbolo de cotizaciónFBIO
Fecha de salida a bolsaNov 17, 2011
Director ejecutivoRosenwald (Lindsay A)
Ejecutivos de Fortress Biotech Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Lindsay A. Rosenwald, M.D.
Dr. Lindsay A. Rosenwald, M.D.
Executive Chairman of the Board, President, Chief Executive Officer
Executive Chairman of the Board, President, Chief Executive Officer
4.59M
--
Mr. Michael S. Weiss, J.D.
Mr. Michael S. Weiss, J.D.
Executive Vice Chairman - Strategic Development, Director
Executive Vice Chairman - Strategic Development, Director
2.28M
--
Mr. Dov Klein, CPA
Mr. Dov Klein, CPA
Independent Director
Independent Director
130.10K
+57.91%
Mr. David Jin
Mr. David Jin
Chief Financial Officer and Head of Corporate Development
Chief Financial Officer and Head of Corporate Development
21.57K
+36.93%
Dr. Lucy Lu, M.D.
Dr. Lucy Lu, M.D.
Chief Strategy Officer
Chief Strategy Officer
5.22K
--
Dr. Jimmie Harvey, Jr., M.D.
Dr. Jimmie Harvey, Jr., M.D.
Independent Director
Independent Director
--
--
Mr. J. Jay Lobell, J.D.
Mr. J. Jay Lobell, J.D.
Independent Director
Independent Director
--
--
Mr. Malcolm I. Hoenlein, Ph.D.
Mr. Malcolm I. Hoenlein, Ph.D.
Independent Director
Independent Director
--
--
Mr. Kevin L. Lorenz, J.D.
Mr. Kevin L. Lorenz, J.D.
Independent Director
Independent Director
--
--
Ms. Jaclyn Jaffe
Ms. Jaclyn Jaffe
Investor Relations
Investor Relations
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Lindsay A. Rosenwald, M.D.
Dr. Lindsay A. Rosenwald, M.D.
Executive Chairman of the Board, President, Chief Executive Officer
Executive Chairman of the Board, President, Chief Executive Officer
4.59M
--
Mr. Michael S. Weiss, J.D.
Mr. Michael S. Weiss, J.D.
Executive Vice Chairman - Strategic Development, Director
Executive Vice Chairman - Strategic Development, Director
2.28M
--
Mr. Dov Klein, CPA
Mr. Dov Klein, CPA
Independent Director
Independent Director
130.10K
+57.91%
Mr. David Jin
Mr. David Jin
Chief Financial Officer and Head of Corporate Development
Chief Financial Officer and Head of Corporate Development
21.57K
+36.93%
Dr. Lucy Lu, M.D.
Dr. Lucy Lu, M.D.
Chief Strategy Officer
Chief Strategy Officer
5.22K
--
Dr. Jimmie Harvey, Jr., M.D.
Dr. Jimmie Harvey, Jr., M.D.
Independent Director
Independent Director
--
--
Desglose de ingresos
Divisa: USDActualizado: 2 de abr de 2025
Divisa: USDActualizado: 2 de abr de 2025
FY2023
FY2023Q4
FY2022
FY2022Q4
FY2021
FY2019
Por negocioUSD
Nombre
Ganancia
Proporción
Targadox®
3.20M
3.79%
Exelderm®
2.40M
2.83%
Ximino®
287.00K
0.34%
La empresa aún no ha revelado los datos relevantes.
Por negocio
Por región
Por negocioUSD
Nombre
Ganancia
Proporción
Targadox®
3.20M
3.79%
Exelderm®
2.40M
2.83%
Ximino®
287.00K
0.34%
Estadísticas de accionistas
Actualizado: lun., 11 de may
Actualizado: lun., 11 de may
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Rosenwald (Lindsay A)
13.81%
Weiss (Michael S)
6.85%
Opaleye Management Inc.
3.28%
Vanguard Capital Management, LLC
2.91%
Summit Financial, LLC
1.32%
Otro
71.83%
Accionistas
Accionistas
Proporción
Rosenwald (Lindsay A)
13.81%
Weiss (Michael S)
6.85%
Opaleye Management Inc.
3.28%
Vanguard Capital Management, LLC
2.91%
Summit Financial, LLC
1.32%
Otro
71.83%
Tipos de accionistas
Accionistas
Proporción
Individual Investor
22.79%
Investment Advisor
9.55%
Hedge Fund
5.62%
Investment Advisor/Hedge Fund
2.48%
Research Firm
0.49%
Venture Capital
0.04%
Otro
59.02%
Participación institucional
Actualizado: mié., 1 de abr
Actualizado: mié., 1 de abr
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2026Q1
113
6.02M
18.14%
-871.67K
2025Q4
92
4.96M
26.50%
--
2025Q3
107
4.96M
27.33%
--
2025Q2
114
4.96M
27.45%
+47.82K
2025Q1
116
4.91M
27.75%
-3.29M
2024Q4
121
4.82M
26.63%
+370.47K
2024Q3
123
4.48M
24.67%
+822.95K
2024Q2
130
3.66M
27.39%
+620.10K
2024Q1
155
3.04M
28.91%
-2.56M
2023Q4
162
4.72M
15.96%
+3.18M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Rosenwald (Lindsay A)
4.59M
14.78%
+475.42K
+11.56%
Mar 18, 2026
Weiss (Michael S)
2.28M
7.33%
+475.42K
+26.40%
Mar 18, 2026
Opaleye Management Inc.
1.09M
3.51%
+1.09M
--
Dec 31, 2025
Summit Financial, LLC
439.93K
1.42%
-4.82K
-1.08%
Dec 31, 2025
Shikiar Asset Management, Inc.
278.47K
0.9%
--
--
Dec 31, 2025
Geode Capital Management, L.L.C.
262.49K
0.85%
+18.07K
+7.39%
Dec 31, 2025
Northern Trust Investments, Inc.
239.53K
0.77%
+18.90K
+8.56%
Dec 31, 2025
Susquehanna International Group, LLP
229.78K
0.74%
-126.40K
-35.49%
Dec 31, 2025
Ver más
ETFs relacionados
Actualizado: sáb., 6 de dic
Actualizado: sáb., 6 de dic
Nombre
Proporción
iShares Micro-Cap ETF
0.01%
Fidelity Enhanced Small Cap ETF
0%
iShares Micro-Cap ETF
Proporción0.01%
Fidelity Enhanced Small Cap ETF
Proporción0%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Fecha ex-dividendo
Tipo
Relación
Oct 09, 2023
Merger
15→1
Oct 09, 2023
Merger
15→1
Oct 09, 2023
Merger
15→1
Oct 09, 2023
Merger
15→1
Fecha
Fecha ex-dividendo
Tipo
Relación
Oct 09, 2023
Merger
15→1
Oct 09, 2023
Merger
15→1
Oct 09, 2023
Merger
15→1
Oct 09, 2023
Merger
15→1
